Generation Bio

Today, Generation Bio's CEO Geoff McDonough, M.D., presented at the TD Cowen Health Care Conference, where he discussed our innovative approach to changing what's possible for people living with T cell-driven autoimmune diseases. To learn more about how we're leveraging our unique cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA selectively to T cells, catch a replay of the presentation here: https://bit.ly/gbioevents #GenerationBio #Biotech #TDCowenConference

We were excited to announce yesterday that we are leveraging our validated T cell-directed lipid nanoparticle (ctLNP) technology to develop siRNA therapeutics for T cell-driven autoimmune diseases. Our innovative approach aims to selectively modulate T cells?in vivo, targeting high-value, currently hard-to-drug targets. Dive deeper into our update by visiting our website and reading our press release. ? In order to support the evolution of our ctLNP-enabled strategy and build out our clinical capabilities, we undertook a reorganization that impacted a group of our employees. We are focused on offering these dedicated, talented people support in finding new opportunities. If you would be interested in our resume book, please reach out to?[email protected]?or comment directly on this post. ? We look forward to providing more updates as we change what's possible for people living with T-cell driven autoimmune diseases.

This past month at Generation Bio, our very own Kelly Castro, MBA, CPA participated in a panel at BeyondTheBlack, a premier accounting conference that brings together industry leaders driving transformation in finance and accounting processes.?Kelly?joined other finance leaders to share her experience with cloud-based solutions to drive efficiency and innovation in the financial close process.?Congratulations?to?Kelly?on her successful presentation!?

Here's a recap of our exciting October at Generation Bio! At the ESGCT 31st Annual Congress, we presented new preclinical data on our cell-targeted lipid nanoparticle (ctLNP) platform. In a non-human primate study conducted as part of our?collaboration?with @Moderna, Inc., a T cell ctLNP delivered mRNA to a majority of circulating T cells, with minimal biodistribution to other organs. This selective delivery to T cells in NHPs marks a significant advancement in our pursuit of in vivo genetic medicines. Stay tuned for more updates on our innovative genetic medicine research! #Biotech #GeneticMedicine #ESGCT2024 To learn more, visit the Scientific Presentations page on our website: https://lnkd.in/eDnPmsRK

Congratulations to Generation Bio Sr. Scientist Anthony Dawson for his presentation at the Cell & Gene Therapy International / BioProcess International Conference last week! Anthony discussed our Rapid Enzymatic Synthesis (RES) process, which is designed to significantly improve the speed, quality, and scalability of DNA manufacturing compared to traditional cell-based methods. If you missed it, you can check out the slides from Anthony's presentation on our website: https://lnkd.in/eDnPmsRK #BioProcessInternational?#BPI2024 #CGT2024